Risk of Nonmelanoma Skin Cancer in Patients With Inflammatory Bowel Disease Who Use Thiopurines Is Not Increased

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 5, 2011, Pages

  van Schaik, Fiona D M ^a   van Oijen, Martijn G H ^a   Smeets, Hugo M ^a   van der Heijden, Geert J M G ^a   Siersema, Peter D ^a   Oldenburg, Bas ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE;

CANCER INCIDENCE; CANCER RISK; CROHN DISEASE; DISEASE ASSOCIATION; DRUG SAFETY; ENTERITIS; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LETTER; NONHODGKIN LYMPHOMA; NONMELANOMA SKIN CANCER; PRESCRIPTION; SKIN CANCER; ULCERATIVE COLITIS;

EID: 79955025395     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.01.021     Document Type: Letter

References (4)

1. Long M.D., Herfarth H.H., Pipkin C.A., et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010, 8:268-274.
2. Kinlen L.J., Sheil A.G., Peto J., et al. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. BMJ 1979, 2:1461-1466.
3. Beaugerie L., Brousse N., Bouvier A.M., et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009, 374:1617-1625.
4. Kandiel A., Fraser A.G., Korelitz B.I., et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54:1121-1125.